PTGS2 and cancer: A wide range of tumor-specific markers and promoters are well known for midkine and cyclooxygenase-2, and these promoter-driven oncolytic adenoviruses kill various types of cancers.23–26 As for the results in this study, it is clear that oncolytic adenovirus driven by IAI.3B promoter has a very wide antitumor spectrum for solid tumors, similar to the oncolytic adenovirus vectors driven by the cyclooxygenase-2 and midkine promoters.